Express Scripts (ESRX)

ESRX (NASDAQ:Health Services)
$84.71
neg -0.09
-0.11%
Today's Range: 84.10 - 85.24 | ESRX Avg Daily Volume: 3,893,700
Last Update: 01/26/15 - 3:59 PM EST
Volume: 3,548,789
YTD Performance: 0.15%
Open: $85.00
Previous Close: $84.80
52 Week Range: $64.64 - $86.64
Oustanding Shares: 733,910,000
Market Cap: 62,375,010,900
6-Month Chart
TheStreet Ratings Grade for ESRX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 12 12 12 12
Moderate Buy 3 3 3 2
Hold 5 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.63 1.55 1.55 1.53
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 34.00
Price Earnings Comparisons:
ESRX Sector Avg. S&P 500
34.00 34.10 26.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
16.07% 13.93% 64.15%
GROWTH 12 Mo 3 Yr CAGR
Revenue 10.90 1.31 0.32
Net Income 40.80 0.60 0.17
EPS 28.00 0.04 0.01
Earnings for ESRX:
EBITDA 6.00B
Revenue 104.10B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $1.38 $1.15 $4.88 $5.44
Number of Analysts 14 9 16 16
High Estimate $1.40 $1.21 $4.90 $5.55
Low Estimate $1.37 $1.11 $4.87 $5.35
Prior Year $1.12 $0.99 $4.33 $4.88
Growth Rate (Year over Year) 23.47% 16.50% 12.70% 11.55%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Bret Jensen

 | Jan 6, 2015 | 10:30 AM EST

They offer a nice shelter for the headwinds now hitting equities.

By

Chris Laudani

 | Dec 30, 2014 | 11:00 AM EST

Its hepatitis C drug will dominate the market.

By

David Katz

 | Dec 26, 2014 | 12:30 PM EST

Its hepatitis C drug is better; the stock trades at a discount.

By

Jim Cramer

 | Dec 23, 2014 | 2:36 PM EST

Here's the best way to play them.

By

Jim Cramer

 | Dec 23, 2014 | 1:11 PM EST

Stocks that do well when the economy rises are shining.

By

Bret Jensen

 | Dec 23, 2014 | 12:00 PM EST

It has a great long-term future.

By

Jim Cramer

 | Dec 22, 2014 | 1:12 PM EST

It might be good for consumers, but not for the stock.

bearishExpress Scripts downgraded at Goldman

Sep 11, 2014 | 6:50 AM EDT

ESRX was downgraded from Buy to Neutral, Goldman Sachs said. $75 price target. Core business is facing fading growth drivers.

By

Bret Jensen

 | Jul 31, 2014 | 9:30 AM EDT

Here are a few stocks I have made solid calls on recently that have moved up.

bearishExpress Scripts price target lowered at Jefferies

Jul 30, 2014 | 8:16 AM EDT

ESRX price target lowered from $86 to $80, Jefferies said. Buy rating. Risk of incremental contract turnover.

Shares of Colgate-Palmolive are under pressure again today. On Friday CL dropped ove...
In a perfect intermediate-term set-up, I would like to see the Market Vectors Gold Miners ...
I suspect with the events of the past couple weeks we won't see much push toward a shift i...
Homegoods retailer Bed, Bath & Beyond (BBBY) was hit hard a couple of weeks ago, dropp...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.